FGF19 and metabolic dysfunction-associated steatohepatitis: As a key downstream target of the nuclear transcription receptor FXR, endocrine FGF19 showed potent regulatory activity of BAs and postprandial lipid and glucose metabolism, which sparks interest in clinical translation of FGF19 or its analogues for cholestatic liver disease and nonalcoholic steatohepatitis (NASH) [44].